Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 16/20 | 0.69 |
| ▸ | ESR1 | P03372 | 15/20 | 0.69 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8234582 | 0.84 | ESR2 (0.62) | ESR2ESR1MAOAUGT1A1MAOB | |
| SCHEMBL8242608 | 0.84 | ESR2 (0.62) | ESR2ESR1MAOAUGT1A1MAOB | |
| SCHEMBL8236050 | 0.83 | ESR2 (0.50) | ESR2ESR1MAOAUGT1A1MAOB | |
| SCHEMBL3922937 | 0.81 | ESR2 (1.00) | ESR2ESR1MAOAUGT1A1MAOB | |
| SCHEMBL8242350 | 0.81 | ESR2 (0.54) | ESR2ESR1MAOAUGT1A1MAOB | |
| SCHEMBL8235168 | 0.80 | ESR2 (0.57) | ESR2ESR1MAOAUGT1A1MAOB | |
| SCHEMBL5139553 | 0.80 | FGFR1 (0.55) | MAOAP2RX7 | |
| SCHEMBL8246534 | 0.80 | ESR2 (0.49) | ESR2ESR1MAOAUGT1A1MAOB | |
| SCHEMBL3575957 | 0.79 | FGFR1 (0.70) | ESR2ESR1MAOAUGT1A1MAOB | |
| SCHEMBL8927863 | 0.76 | ESR2 (0.65) | ESR2ESR1MAOAUGT1A1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877747-B2 | Indenone derivative and pharmaceutical composition comprising same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2014-11-04 | — | — | US | disclosed |
| US-8877747-B2 | Indenone derivative and pharmaceutical composition comprising same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2014-11-04 | — | — | US | disclosed |
| US-8877747-B2 | Indenone derivative and pharmaceutical composition comprising same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2014-11-04 | — | — | US | disclosed |
| EP-2475649-B1 | INDENONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | KOREA RES INST CHEM TECH (KR) | 2014-08-13 | — | — | EP | disclosed |
| EP-2475649-B1 | INDENONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | KOREA RES INST CHEM TECH (KR) | 2014-08-13 | — | — | EP | disclosed |
| US-20120214991-A1 | Indenone Derivative and Pharmaceutical Composition Comprising Same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-08-23 | — | — | US | disclosed |
| US-20120214991-A1 | Indenone Derivative and Pharmaceutical Composition Comprising Same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-08-23 | — | — | US | disclosed |
| US-20120214991-A1 | Indenone Derivative and Pharmaceutical Composition Comprising Same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-08-23 | — | — | US | disclosed |
| EP-2475649-A1 | INDENONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Korea Research Institute Of Chemical Technology (KR) | 2012-07-18 | — | — | EP | disclosed |
| WO-2011030955-A1 | INDENONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011030955-A1 | INDENONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214991-A1 | Indenone Derivative and Pharmaceutical Composition Comprising Same | INSR, HSD17B7, SOST | ESR2 325/4885ESR1 1113/4885MAOA 3574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.